Vasopressin mechanism-mediated pressor responses caused by central angiotensin II in the ovine fetus.
AVP not only influences renal water excretion but also has profound cardiovascular effects in adults. Our recent studies have demonstrated that central angiotensin induced fetal pressor responses accompanied with AVP release. However, little is known of hormonal mechanisms in angiotensin-mediated fetal blood pressure (BP) changes. The present study determined AVP mechanisms in central angiotensin-mediated fetal pressor responses. The V1-receptor antagonist or V2-receptor antagonist was infused intravenously into the ovine fetus at 90% gestation. Angiotensin II (Ang II; 1.5 microg/kg) was then injected intracerebroventricularly into the chronically instrumented fetus. Ang II produced a significant increase in fetal systolic, diastolic, and mean arterial pressure adjusted to amniotic pressure (A-MAP). The enhanced fetal A-MAP was associated with intense c-fos expression in the central putative cardiovascular area: the paraventricular nuclei (PVN). Double labeling demonstrated that a number of the AVP-containing neurons in the PVN were expressing c-fos in response to central Ang II. Consistent with the activation of AVP neurons in the PVN, fetal plasma AVP was markedly enhanced. Fetal i.v. V1-receptor antagonist or V2-receptor antagonist had no effect on either fetal or maternal baseline BP. However, intracerebroventricular Ang II-increased BP was partially inhibited, although not completely abolished, by the V1-receptor blockade. In contrast, fetal i.v. infusion of V2-receptor antagonist had no effect on the pressor responses induced by central Ang II. The results suggest that the central Ang II-mediated pressor responses at the last third of gestation is mediated partially by the AVP mechanism via V1 not V2 receptors.
Shi
Lijun
L
Harbor-UCLA Medical Center, 1124 West Carson Street, RB-1, Torrance, CA 90502, USA.
Guerra
Catalina
C
Yao
Jiaming
J
Xu
Zhice
Z
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism; D011247:Pregnancy; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000378:metabolism; D012756:Sheep; D013495:Supraoptic Nucleus / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D016760:Proto-Oncogene Proteins c-fos; D017483:Receptors, Vasopressin; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D001127:Arginine Vasopressin